Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy

Antiviral Therapy

Volumn 9, Issue 5, 2004, Pages 649-663

  Martínez, Esteban ^a   Tuset, Montserrat ^a   Milinkovic, Ana ^a   Miro, José M ^a   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; BIGUANIDE DERIVATIVE; CHOLESTEROL; DELAVIRDINE; EFAVIRENZ; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONSTIPATION; DIABETES MELLITUS; DIETARY INTAKE; DYSLIPIDEMIA; DYSPEPSIA; EXERCISE; FEMALE; FLUSHING; GALLSTONE; GASTROINTESTINAL TOXICITY; GOUT; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; KIDNEY FAILURE; LIFESTYLE; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIPOPROTEIN METABOLISM; LIVER TOXICITY; MALE; METABOLIC DISORDER; MYOPATHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INFECTION;

ANTILIPEMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLOFIBRIC ACID; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS;

EID: 7244244205     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338:853-860.
2. Richman DD. HIV chemotherapy. Nature 2001; 410:995-1001.
3. Fischl MA. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. AIDS 1999; 13(Suppl. 1):S49-S59.
4. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC & Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. Journal of Acquired Immune Deficiency Syndromes 2000; 23:35-43.
5. Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, Rieger A, Wagner OF & Quehenberger P. Sex differences in HAART-associated dyslipidaemia. AIDS 2001; 15:725-734.
6. Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R & Mooser V, for the Swiss HFV Cohort Study. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100:700-705.
7. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, Locke C & Brunzell JD. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14:51-57.
8. Roberts AD, Muesing RA, Parenti DM, Hsia J, Wasserman AG & Simon GL. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clinical Infectious Diseases 1999; 29:441-443.
9. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M & Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18.
10. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17(Suppl. 1):S141-S148.
11. Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Gonget I, Blanch J, Phillips A & Gatell JM. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-598.
12. Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E & Gatell JM, for the Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. New England Journal of Medicine 2003; 349:1036-1046.
13. Manfredi R & Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. Journal of Infection 2001; 42:181-188.
14. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV & Montaner JSG. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231-239.
15. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D & Glesby MJ, for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Diseases 2003; 37:613-627.
16. Gutiérrez F, Padilla S, Navarro A, Masiá M, Hernández I, Ramos J, Esteban A & Martin-Hidalgo A. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. Journal of Acquired Immune Deficiency Syndromes 2003; 33:594-600.
17. Calza L, Manfredi R, Farneti B & Chiodo F. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. International Journal of Antimicrobial Agents 2003; 22:54-59.
18. Green ML. Evaluation and management of dyslipidemia in patients with HIV infection. Journal of General Internal Medicine 2002; 17:797-810.
19. Kumar P, Rodriguez-French A, Thompson M, Tashima K, Williams V, Wannamaker P & Shaefer M. Prospective study of hyperlipidemia in ART-naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002). 9th Conference on Retroviruses & Opportunistic Infections. 23 February 2002, Seattle, Wash., USA. Available at: http://www.retroconference.org/2002/Abstract/13081.htm. Last access 8 March 2004. Abstract 33.
20. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction [erratum New England Journal of Medicine 2004; 350:955]. New England Journal of Medicine 2003; 349:1993-2003.
21. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction [erratum New England Journal of Medicine 2004; 350:955]. New England Journal of Medicine 2003; 349:1993-2003.
22. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE & Janssen RS, and the HIV Outpatient Study (HOPS) Investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748.
23. Mary-Krause M, Cotte L, Simon A, Partisani M & Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
24. Berk PD, Blaschke TF, Scharschmidt BF, Waggoner JG & Berlin NI. A new approach to quantitation of the various sources of bilirubin in man. Journal of Laboratory & Clinical Medicine 1976; 87:767-780.
25. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R & Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. Journal of the American Medical Association 2003; 289:2978-2982.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III). Final Report. NIH 02-5215. 2002. Bethesda, Md.: National Heart, Lung, and Blood Institute, National Cholesterol Education Program; NIH.
27. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P & Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Journal of Clinical Endocrinology & Metabolism 1992; 74:1045-1052.
28. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P & Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. Journal of Clinical Endocrinology & Metabolism 1993; 76:1423-1427.
29. Hellerstein MK, Grunfeld C, Wu K, Christiansen M, Kaempfer S, Kletke C & Shackleton CHL. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. Journal of Clinical Endocrinology & Metabolism 1993; 76:559-565.
30. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, Mantero-Atienza E & Baum MK. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. American Journal of Medicine 1993; 94:515-520.
31. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H & Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. Journal of Acquired Immune Deficiency Syndromes 1994; 7:1149-1156.
32. Tsiodras S, Mantzoros C, Hammer S & Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Archives of Internal Medicine 2000; 160:2050-2056.
33. Clevenbergh P, Garraffo R & Dellamonica P. Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients. HIV Clinical Trials 2003; 4:330-336.
34. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, Hirschel B, Vernazza P, Francioli P, Greub G, Flepp M & Telenti A. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-1327.
35. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD & Sosman JM. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
36. Petit JM, Duong M, Duvillard L, Piroth L, Grappin M, Verges B, Chavanet P, Brun JM & Portier H. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Hormone & Metabolic Research 2000; 32:367-372.
37. Moyle GJ & Baldwin C. Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy [letter]. Journal of Acquired Immune Deficiency Syndromes 1999; 21:423-424.
38. Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, Thiry A, Schnittman S & Sension M. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003; 17:1339-1349.
39. Murphy RL, Sanne I, Cahn P, Phanupak P, Percival L, Kelleher T & Giordano M. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17:2603-2614.
40. Sanne I, Piliero P, Squires K, Thiry A & Schnittman S, for the AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. Journal of Acquired Immune Deficiency Syndromes 2003; 32:18-29.
41. Staszewski S, Gallant JE, Pozniak AL, Suleiman JM, DeJesus E, Lu B, Sayre J & Cheng A. Favorable metabolic profile for tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral-naive patients: 96-week interim results. 2nd International AIDS Society Conference on HIV Pathogenesis & Treatment. 13-16 July 2003, Paris, France. Poster 562.
42. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HO & Reiss P, on behalf of the Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile. AIDS 2001; 15:2407-2414.
43. van Leth F, Phanuphak P, Gazzard B, Cahn P, Wood R, Bloch M, Katlama C, Schechter M, Murphy R, Horban A, Hall A, van der Valk M, Lange J & Reiss P. Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN Study). 10th Conference on Retroviruses & Opportunistic Infections. 13 February 2003, Boston, Mass., USA. Available at: http://www.retroconference.org/2003/Abstract/ Abstract.aspx?AbstractID=9. Last access 8 March 2004. Abstract 97.
44. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
45. Mallal SA, John M, Moore CB, James IR & McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
46. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ & Danner SA, on behalf of the Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001; 15:847-855.
47. Nolan D, Hammond E, James I, McKinnon E & Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Therapy 2003; 8:617-626.
48. Martinez E, Milinkovic A, Garcia M, Perez-Cuevas JB, Blanco JL, Murillas J, Lonca M, Mallolas J & Gatell JM. Risk of lipodystrophy in HIV-1-infected patients receiving highly active antiretroviral therapy not containing protease inhibitors: a prospective cohort study. 14th International AIDS Conference. 17-12 July 2002, Barcelona, Spain. Available at: http://www.aids2002.com/ Program/ViewAbstract.asp?id=/T-CMS_Content/Abstract/200206290750411066.xml. Last access 29 August 2003. Abstract ThPeB7355.
49. Moyle G. Lipodystrophy: lack of agreement on definition and etiology presents a challenge to research and therapy. AIDS Reader 2002; 12:438-442.
50. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clinical Infectious Diseases 2000; 30(Suppl. 2):S135-S142.
51. Carr A, Miller J, Law M & Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:F25-F32.
52. Nolan D, John M & Mallal S. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antiviral Therapy 2001; 6:145-160.
53. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
54. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, Stolf M & Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-F70.
55. Churchill DR, Pym AS, Babiker AG, Back DJ & Weber JN. Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection. British Journal of Clinical Pharmacology 1998; 46:518-519.
56. Walli R, Herfort O, Michl GM, Demant T, Jäger H, Dieterle C, Bogner JR, Landgraf R & Goebel FD. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:F167-F173.
57. Carr A, Samaras K, Chisholm DJ & Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883.
58. Penzak SR & Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scandinavian Journal of Infectious Diseases 2000; 32:111-123.
59. Lenhard JM, Croom DK, Weiel JE & Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arteriosclerosis, Thrombosis, & Vascular Biology 2000; 20:2625-2629.
60. del Castillo-Olivares A & Gil G. Differential effects of sterol regulatory binding proteins 1 and 2 on sterol 12α-hydroxylase. SREBP-2 suppresses the sterol 12α-hydroxylase promoter. Journal of Biological Chemistry 2002; 277:6750-6757.
61. Riddle TM, Kuhel DG, Woollen LA, Fichtenbaum CJ & Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. Journal of Biological Chemistry 2001; 276:37514-37519.
62. Nguyen AT, Gagnon A, Angel JB & Sorisky A. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS 2000; 14:2467-2473.
63. Miserez AR, Muller PY & Spaniol V. Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS 2002; 16:1587-1594.
64. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P & Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
65. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsoerg HN & Sturley SL. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nature Medicine 2001; 7:1327-1331.
66. Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG & Saag MS. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. Journal of Acquired Immune Deficiency Syndromes 2002; 31:257-275.
67. Wang S, Mulvey R, Laing N, Flint O & Parker RA. Differentiation of atazanavir from other HIV-protease inhibitors in preclinical models of glucose uptake, lipogenesis, and proteasome function. Antiviral Therapy 2002; 7:L6. Abstract 10.
68. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz J-M, Aweeka FT, Mulligan K, Schambelan M & Grunfeld C. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18:641-649.
69. Gottp AM Jr & Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease; a working group report and update. Journal of the American College of Cardiology 2004; 43:717-724.
70. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP & Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. New England Journal of Medicine 2004; 350:1505-1515.
71. Bonnet F, Savès M, Droz C, Peuchant E, Chêne G, Beylot J & Morlat P. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens [letter]. Journal of Acquired Immune Deficiency Syndromes 2000; 25:199-200.
72. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, Simonoff M, Brossard G, Barbeau P, Fleury H, Clerc M, Leng B & Conri C. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. European Journal of Clinical Investigation 1994; 24:416-420.
73. Dubé MP, Shankar S, Vanderluitgaren JM, Leffler CM, Baron AD & Steinberg HO. Effect of indinavir (IDV) monotherapy on endothelial function in men without HIV infection. 9th Conference on Retroviruses & Opportunistic Infections. 28 February 2002, Seattle, Wash., USA. Available at: http://63.126.3.84/2002/Abstract/14099.htm. Last access 4 June 2002. Abstract LB10.
74. Meng Q, Lima JAC, Lai H, Vlahov D, Celentano DD, Strathdee SA, Nelson KE, Wu KC, Chen S, Tong W & Lai S. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. American Heart Journal 2002; 144:642-648.
75. Chironi G, Escaut L, Gariepy J, Cogny A, Teicher E, Monsuez J-J, Levenson J, Simon A & Vittecoq D. Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2003; 32:490-493.
76. Currier J, Kendall M, Henry K, Torriani F, Storey S, Shikuma C, Mickelberg K, Alston B, Basar M, Zackin R & Hodis H. Carotid intima-media thickness in HIV-infected and uninfected adults: ACTG 5078. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, Mass., USA. Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx? AbstractID=1236. Last access 6 May 2004. Abstract 131.
77. Mercie P, Thiebaut R, Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Morlat P, Ragnaud JM, Dupon M, Malvy D, Bellet H, Lawson-Ayayi S, Roudaut R & Dabis F. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Annals of Medicine 2002; 34:55-63.
78. Rickerts V, Brodt HR, Staszewski S & Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. European Journal of Medical Research 2000; 5:329-333.
79. Iloeje U, Yuan Y, Tuomari A, L'Italien G, Mauskopf J & Moore R. Protease inhibitors may increase risk of cardiovascular disease in HIV-infected patients. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, Mass., USA. Available at: http://www.retroconference.org/ 2003/Abstract/Abstract.aspx?AbstractID=630. Last access 6 May 2004. Poster 746.
80. Moore RD, Keruly JC & Lucas G. Increasing incidence of cardiovascular disease in HIV-infected persons in care. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, Mass., USA. Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID=217. Last access 8 March 2004. Abstract 132.
81. Hadigan C, Meigs JB, Wilson PWF, D'Agostino RB, Davis B, Basgoz N, Sax PE & Grinspoon S. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clinical Infectious Diseases 2003; 36:909-916.
82. Currier J, Taylor A, Boyd F, Kawabata H, Maa J, Dezii C, Burtcel B & Hodder S. Coronary heart disease (CHD) in HIV infected individuals: associations with antiretroviral therapy. Antiviral Therapy 2002; 7:L37. Abstract 54.
83. Bozzette SA, Ake CF, Tam HK, Chang SW & Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. New England Journal of Medicine 2003; 348:702-710.
84. Klein D & Hurley L. Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: additional follow-up. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, Mass., USA. Available at: http://www.retroconference.org/2003/Abstract/ Abstract.aspx?AbstractID=2184. Last access 8 March 2004. Abstract 747.
85. David MH, Hornung R & Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clinical Infectious Diseases 2002; 34:98-102.
86. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001; 285:2486-2497.
87. Meienberg F, Battegay E, Bucher HC & Battegay M. The use of lipid-lowering agents in HIV-infected patients. Journal of HIV Therapy 2001; 6:40-44.
88. Denke MA. Cholesterol-lowering diets. A review of the evidence. Archives of Internal Medicine 1995; 155:17-26.
89. Knopp RH, Walden CE, Retzlaff BM, McCann BS, Dowdy AA, Albers JJ, Gey GO & Cooper MN. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study. Journal of the American Medical Association 1997; 278:1509-1515.
90. Walden CE, Retzlaff BM, Buck BL, McCann BS & Knopp RH. Lipoprotein lipid response to the National Cholesterol Education Program step II diet by hypercholesterolemic and combined hyperlipidemic women and men. Arteriosclerosis, Thrombosis, & Vascular Biology 1997; 17:375-382.
91. Henry K, Melroe H, Huebesch J, Hermundson J & Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352:1031-1032.
92. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S & Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001; 15:1503-1508.
93. Saag MS, Powderly WG, Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon S, Grunfeld C, Kotler DP & Mulligan K. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: summary of selected trials. Topics in HIV Medicine 2002; 10:47-51.
94. Drechsler H & Powderly WG. Switching effective antiretroviral therapy: a review. Clinical Infectious Diseases 2002; 35:1219-1230.
95. Murphy RL & Smith WJ. Switch studies: a review. HIV Medicine 2002; 3:146-155.
96. McComsey G, Bhumbra N, Ma J-F, Rathore M & Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 2003; 111:e275-e281.
97. Murphy R, Pokrovsky V, Rozenbaum W, Wood R, Percival L, Odeshoo L & Giotdano M. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS Study 008/044. 10th Conference on Retroviruses & Opportunistic Infections. 11 February 2003, Boston, Mass., USA. Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID=2075. Last access 4 February 2004. Abstract and Poster 555.
98. Lichtenstein K, Clumeck N, Bellos N, Rodriguez C, Estrada V, Gialelis K, Sankoh S & Ledesma E. Improvement in lipid levels in antiretroviral- experienced HIV-infected patients who are failing therapy and are switched to an atazanavir-containing regimen. Antiviral Therapy 2003; 8:L79-L80. Abstract 119.
99. Knopp RH. Drug treatment of lipid disorders. New England Journal of Medicine 1999; 341:498-511.
100. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
101. Dresser GK, Spence JD & Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clinical Pharmacokinetics 2000; 38:41-57.
102. Herman RJ. Drug interactions and the statins. Canadian Medical Association Journal 1999; 161:1281-1286.
103. Fichtenbaum CJ & Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clinical Pharmacokinetics 2002; 41:1195-1211.
104. Baldini F, Di Giambenedetto S, Cingolani A, Murri R, Ammassari A & De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS 2000; 14:1660-1662.
105. Carr RA, Andre AK, Bertz RJ, Hsu A, Lam W, Chang M, Chen P, Williams L, Bernstein B & Sun E. Concomitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokinetic (PK) interaction with atorvastatin (ATO) but not pravastatin (PRA). 40th Interscience Conference on Antimicrobial Agents & Chemotherapy. 17-20 September 2000, Toronto, Ont., Canada. Abstract 1644.
106. Martin CM, Hoffman V & Berggren RE. Rhabdomyolysis in a patient receiving simvastatin concurrently with highly active antiretroviral therapy. 40th Interscience Conference on Antimicrobial Agents & Chemotherapy. 17-20 September 2000, Toronto, Ont., Canada. Abstract 1297.
107. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH & Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrobial Agents & Chemotherapy 2001; 45:3445-3450.
108. Gallicano K, Foster B & Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. British Journal of Clinical Pharmacology 2003; 55:199-202.
109. Moyle GJ, Buss NE & Gazzard BG. Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy [letter]. Journal of Acquired Immune Deficiency Syndromes 2002; 30:460-462.
110. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD & Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. Journal of Pharmaceutical Sciences 1998; 87:803-807.
111. Eagling VA, Back DJ & Barry MG. Differential Inhibition of Cytochrome P450 Isoforms by the Protease inhibitors, ritonavir, saquinavir and indinavir. British Journal of Clinical Pharmacology 1997; 44:190-194.
112. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents [updated 23 March 2004]. Available at: http://aidsinfo.nih.gov/guidelines/adult/ AA_032304.pdf. last access 23 March 2004.
113. Flockhart DA. Cytochrome P450 Drug Interaction Table. Available at: http://medicine.iupui.edu/flockhart/table.htm. Last access 6 May 2004.
114. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B & Aweeka F, and the NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-577.
115. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J & Wilpshaar JW. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. American Heart Journal 2002; 144:1044-1051.
116. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H & Miller E. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. American Heart Journal 2002; 144:1036-1043.
117. Miller J, Brown D, Amin J, Kent-Hughes J, Law M, Kaldor J, Cooper DA & Carr A. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002; 16:2195-2200.
118. Hewitt RG, Shelton MJ & Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS 1999; 13:868-869.
119. Calza L, Manfredi R & Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002; 30:26-31.
120. Aberg J, Zackin R, Evans S, Yang Y, Alston B, Henry WK, Glesby M, Brobst S, Owens SI & Fichtenbaum CJ. A prospective, multicenter, randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: ACTG 5087. 40th Annual Meeting of the Infectious Disease Society of America (IDSA). 26 October 2002, Chicago, Ill., USA. Abstract 26.
121. Garg A & Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. Journal of the American Medical Association 1990; 264:723-726.
122. Gerber M, Yarasheski K, Dreschsler H, Mondy K, Claxton S, Stoneman J, Powderly WG & Tebas P. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, Mass., USA. Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx? AbstractID=1674. Last access 29 July 2003. Abstract 1674.
123. Fessel WJ, Follansbee SE & Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS 2002; 16:1785-1789.
124. Brown WV. Cholesterol absorption inhibitors: defining new options in lipid management. Clinical Cardiology 2003; 26:259-264.
125. Kosoglou T, Guillaume M, Sun S, Pember LJC, Reyderman L, Statkevich P, Cutler DL, Veltri EP & Affrime MB. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe. Atherosclerosis Supplements 2001; 2:38. Abstract W6.1.
126. Loignon M & Toma E. L-Carnitine for the treatment of highly active
127. Saint-Marc T & Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999; 13:1000-1002.
128. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P & Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. Journal of the American Medical Association 2000; 284:472-477.
129. Hadigan C, Rabe J & Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. Journal of Clinical Endocrinology & Metabolism 2002; 87:4611-4615.
130. Walli R, Michl GM, Mühlbayer D, Brinkmann L & Goebel FD. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Research in Experimental Medicine 2000; 199:253-262.
131. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M & Yki-Järvinen H. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antiviral Therapy 2003; 8:199-207.
132. Yki-Järvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P & Hamsten A. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arteriosclerosis, Thrombosis, & Vascular Biology 2003; 23:688-694.
133. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S & Cooper DA, for the Rosey Investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429-438.
134. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CEM, Brebbia JS, Wax MR & McNurlan MA. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. Journal of Acquired Immune Deficiency Syndromes 2002; 31:163-170.